A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

2000 • 967 citations

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1995 • 800 citations

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

2003 • 737 citations

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

2000 • 586 citations

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

2000 • 426 citations

Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers

2002 • 375 citations

Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?

2001 • 345 citations

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

1999 • 344 citations

Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses In Vivo

1999 • 343 citations

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

2004 • 330 citations

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

2000 • 325 citations

The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

2002 • 321 citations

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

2002 • 308 citations

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

2001 • 278 citations

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

1991 • 256 citations

In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020: Construction and Evaluation in Rodents

1988 • 252 citations

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

2001 • 238 citations

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1998 • 236 citations

Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene

2000 • 232 citations

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1

2001 • 224 citations

The Herpes Simplex Virus US11 Protein Effectively Compensates for the γ134.5 Gene if Present before Activation of Protein Kinase R by Precluding Its Phosphorylation and That of the α Subunit of Eukaryotic Translation Initiation Factor 2

1998 • 185 citations

A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function.

1996 • 158 citations

In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (Aotus trivirgatus)

1990 • 154 citations

Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma

2001 • 130 citations

Oncolytic viral therapies

2004 • 126 citations

Tumor Growth Inhibition by Intratumoral Inoculation of Defective Herpes Simplex Virus Vectors Expressing Granulocyte–Macrophage Colony-Stimulating Factor

2000 • 119 citations

Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy

1996 • 115 citations

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation

2000 • 114 citations

Vaccines in cancer: GVAX®, a GM-CSF gene vaccine

2005 • 106 citations

GM-CSF Gene-Transduced Tumor Vaccines

2005 • 101 citations

ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro

1994 • 84 citations

A Herpesvirus Ribosome-Associated, RNA-Binding Protein Confers a Growth Advantage upon Mutants Deficient in a GADD34-Related Function

1999 • 78 citations

Interleukin 12 Secretion Enhances Antitumor Efficacy of Oncolytic Herpes Simplex Viral Therapy for Colorectal Cancer

2001 • 70 citations

Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir Treatment

1996 • 62 citations

Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma

2002 • 31 citations

Herpes Simplex Virus Glycoproteins: Isolation of Mutants Resistant to Immune Cytolysis

1980 • 30 citations

The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer.

2000 • 24 citations

Deleted Work

1955 • 0 citations